Amidst the resounding success of Novo’s SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.  

Uniting the industry decision-makers behind the explosion of GLP-1 assets, the GLP-1-Based Therapeutics Summit stands as a pivotal platform. Uniquely positioned, it serves as the nexus for industry decision-makers, providing invaluable insights to guide therapeutic strategies, enabling the development of the right drugs for patients at the right price. With Madrigal Pharmaceuticals attending as the first-ever company to gain approval for it's NASH therapies, this summit is symbolizes a landmark for the convergence of innovation and industry success. 

Built with insights from industry giants including Eli Lilly, Novo Nordisk, Amgen, Carmot Therapeutics, Altimmune, and Pfizer, join 60+ industry leaders in Product Planning, Clinical Development, Medical Research, and Commercial Strategy.